Among infants at increased risk for severe #RespiratorySyncytialVirus disease, clesrovimab was well tolerated in the first season, with a safety profile comparable to palivizumab. Medically attended lower respiratory infection and hospitalization associated with respiratory syncytial virus were also similar between groups during season 1. https://ja.ma/4gXcfvs
JAMA Pediatrics’ Post
Explore content categories
- Career
- Productivity
- Finance
- Soft Skills & Emotional Intelligence
- Project Management
- Education
- Technology
- Leadership
- Ecommerce
- User Experience
- Recruitment & HR
- Customer Experience
- Real Estate
- Marketing
- Sales
- Retail & Merchandising
- Science
- Supply Chain Management
- Future Of Work
- Consulting
- Writing
- Economics
- Artificial Intelligence
- Employee Experience
- Workplace Trends
- Fundraising
- Networking
- Corporate Social Responsibility
- Negotiation
- Communication
- Engineering
- Hospitality & Tourism
- Business Strategy
- Change Management
- Organizational Culture
- Design
- Innovation
- Event Planning
- Training & Development